Phase I Eligibility, DLT Adjudication, and Consent on a First-in-Human ATR Inhibitor Trial

She does not currently meet three eligibility criteria: ANC 1.3 (<1.5), platelets 92 (<100), and AST 2.7x ULN (>2.5x). CrCl 52 and bilirubin 1.0 are acceptable.

Do not enroll on the hope that screening labs will 'improve enough.' Each criterion needs a documented, protocol-permitted route.

• AST 2.7x: look for a reversible cause before declaring her ineligible. She is on simvastatin 40 mg - hold it and repeat LFTs in 1-2 weeks; also check for biliary obstruction (imaging), alcohol, and acetaminophen use. If AST falls to <=2.5x, she is eligible.
• ANC 1.3 and platelets 92: likely disease- and treatment-related marrow suppression. Most protocols forbid growth factor support within ~14 days and platelet transfusion within ~7-14 days of first dose, so 'treating to qualify' may itself be a deviation unless the protocol permits it. Clarify with the sponsor/medical monitor in writing before any intervention.
• Rescreening: most protocols allow one repeat screening within the window; repeat labs after the washout period, not the same day.

Medication reconciliation:

• Aprepitant is a moderate CYP3A4 inhibitor (and inducer) and is likely a prohibited concomitant medication for a sensitive CYP3A4 substrate; switch to ondansetron or olanzapine, checking QT.
• Simvastatin is not an inhibitor, but if the investigational agent inhibits CYP3A4, myopathy risk rises; switch to pravastatin or rosuvastatin as a precaution and to remove the confounder of her AST elevation.
• Omeprazole (CYP2C19 inhibitor) is usually acceptable; confirm against the prohibited-medication list rather than assuming.

You cannot answer the DLT question without the protocol's definition - this is the crux. Read it before acting.

Most modern protocols define hepatic DLT as: grade 4 ALT/AST, or grade 3 elevation that persists >7 days, or any grade 3 ALT with concurrent total bilirubin >2x ULN (Hy's law pattern), or grade 3 with clinical sequelae. A transient, asymptomatic grade 3 ALT that resolves to <=grade 1 within 7 days is frequently not a DLT.

Immediate steps:

1. Hold study drug per protocol until the event is adjudicated; do not continue 'while watching.'
2. Repeat AST/ALT, bilirubin, INR, and alkaline phosphatase twice weekly; add viral hepatitis serologies, EBV/CMV, autoimmune markers (ANA, anti-smooth muscle antibody), and review all hepatotoxins including acetaminophen, herbal products, and the statin.
3. Confirm no biliary obstruction with imaging if alkaline phosphatase is disproportionately elevated.
4. Document causality (likely related - she is on a first-in-human agent with hepatic DLT potential) and the temporal relationship to dosing.

Adjudication and reporting:

• If it resolves within 7 days and is asymptomatic, it is probably not a DLT; the cohort may continue, and she may resume at the same or a reduced dose after discussion with the medical monitor.
• If it persists >7 days, or bilirubin climbs >2x ULN, or she develops symptoms, declare it a DLT: that cohort expands to 6 patients and dose escalation pauses.
• Reporting: a grade 3 asymptomatic ALT is not an SAE unless she is hospitalized or it is life-threatening, but it is still a significant AE - enter it in the CRF, report to the sponsor within the protocol's timeline (often 24 hours for grade 3+), and notify the IRB per institutional policy for an unanticipated problem. Source documentation must show the date, grade, causality, and action taken.

Address the therapeutic misconception directly but without undermining her oncologist.

• Reframe the trial's purpose: the primary endpoints are safety, tolerability, pharmacokinetics, and identification of the maximum tolerated dose - not efficacy. In a 3+3 design she may receive a dose later shown to be subtherapeutic, and she may be one of only a handful of patients treated at any given level.
• Give honest, non-numeric-if-unknown expectations: single-agent phase I response rates across solid tumors are historically in the low single digits to ~10%, with higher rates in biomarker-selected populations. Ask the investigator what is known - do not invent a number.
• Be explicit that consent is not a contract: she may withdraw at any time, and declining the trial does not compromise her access to supportive or standard care.
• Discuss the real burdens: frequent PK draws, on-site visits, tumor biopsies if required, diary completion, travel, drug-interaction restrictions (no aprepitant, no grapefruit, no St. John's wort), and the possibility of receiving placebo-free but inactive dose levels.
• Present alternatives honestly - other trials (including other PARP-related or chemotherapy combinations), further cytotoxic therapy, or a hospice/best supportive care pathway - and make clear that choosing supportive care is a legitimate option, not a failure.

Documentation: a note that the purpose of the trial, the uncertainty of benefit, the alternatives, and her right to withdraw were discussed in plain language; that teach-back was used; and that she confirmed understanding. If the consent was signed before this conversation, document the re-consent discussion. Alert the investigator so the message to the patient is consistent across the team.